Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Typhoid conjugate vaccine (Vi-CRM197) - Biological E/Novartis Vaccines Institute for Global Health

Next Previous
Drug Profile

Typhoid conjugate vaccine (Vi-CRM197) - Biological E/Novartis Vaccines Institute for Global Health

Alternative Names: NVGH glycoconjugate vaccine against S. typhi - Novartis; NVGH Vi-CRM197 vaccine; Salmonella monovalent typhi vaccine - NVGH; Typhoid conjugate vaccine - Novartis; Vi-CRM197; Vi-CRM197 glycoconjugated vaccine; Vi-CRM197 vaccine

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Vaccines Institute for Global Health
  • Class Bacterial vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Typhoid

Most Recent Events

  • 28 Jul 2022 Typhoid conjugate vaccine (Vi-CRM197) is still in phase III trials for Typhoid (In adolescents, In adults, In children, In infants, Prevention) in India (IM)
  • 16 Mar 2020 Phase-III clinical trials in Typhoid (Prevention, In adolescents, In adults, In children, In infants) in India (IM) (CTRI2019-07-020451)
  • 30 Jan 2020 Biological E Limited completes a phase I trial for Typhoid (Prevention) in India, before January 2020 (IM) (CTRI2018-03-012558)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top